We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Featured Product
Advertisement

Human Hepatocytes, Cryopreserved, Plateable and Interaction Qualified

Lonza's cryopreserved, plateable human hepatocytes, HUCPI, are characterized for 3 major mechanisms of DDI, transporter activity, enzyme activity, and enzyme gene induction potential. 

Additionally, the hepatocytes are tested and characterized for:  

• Inducibility of enzyme activity for CYP3A4, CYP2B6, and CYP1A2

• Inducibility of mRNA for CYP3A4, CYP2B6, CYP1A2, and CYP2C8 genes

• Actual rate of uptake or efflux for OATP1B1/3, OCT1/2, NTCP, and BSEP transporters

• Basal metabolism for 8 CYPs, SULT, UGT, and aldehyde oxidase

• Characterized for long-term culture potential (> 7 days)

• Characterized for spheroid formation potential

• Characterized for 96-well compatibility

Lonza's qualification methods for cryopreserved human hepatocytes are modeled after recommendations from the FDA publication In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies Guidance for Industry (2017)


Lonza's hepatocytes are isolated with donor-matched non-parenchymal (NPC), Kuppfer Cells, Stellate Cells, and Liver Sinusoidal Endothelial Cells.  All liver-derived cells have an optimized media system for thawing, plating, and maintenance. 


Lonza's scientists have developed optimized protocols for 3D growth in spheroid format for mono-cultures of hepatocytes and co-cultures of hepatocytes and NPCs.  This format provides a robust model for studying acute and chronic toxicities.


Product Specifications
Inducibility of enzyme activity for CYP3A4, CYP2B6, and CYP1A2 Reported
Inducibility of mRNA for CYP3A4, CYP2B6, CYP1A2, and CYP2C8 genes Reported
Basal metabolism for 8 CYPs, SULT, UGT, and aldehyde oxidase Reported
Rate of uptake or efflux for OATP1B1/3, OCT1/2, NTCP, and BSEP transporters Reported
HLA Typing Reported
Characterized for spheroid formation potential Reported
Characterized for 96-well compatibility Reported
Characterized for long-term culture potential (> 7 days) Reported
Viability > 80%
Cell Count (cells/amp) > 5,000,000
About Lonza
Lonza is a healthcare manufacturing organization helping pharmaceutical, biotech and nutrition companies to bring their treatments to market. They help their customers to deliver new and innovative medicines that treat a wide range of diseases, allowing their patients to benefit from life-saving and life-enhancing treatments.
Interested in seeing more content from Lonza?
Discover all their latest news, webinars, products and more by clicking the link below.